Health Canada warns about unauthorized peptide products sold online

Health Canada has issued an updated notice about peptide products promoted and sold without Canadian authorization. The products are advertised for purposes such as weight loss, muscle building, recovery and anti-aging. The notice is a warning about unauthorized products and their uncertain quality—not a statement that every peptide, prescribed treatment or compounded preparation is unsafe or unlawful.

The distinction matters for pharmacy teams. Some peptide-based medicines have been reviewed and authorized for specific uses. A product being described as a “peptide,” or appearing on a website beside wellness products, does not establish that it has been assessed by Health Canada or that it is the same as an authorized medicine.

What authorization means

Health Canada says unauthorized health products have not been assessed for safety, effectiveness and quality under the applicable Canadian pathway. Authorized drugs have a Drug Identification Number (DIN); natural health products have a product number. An online seller’s claims, a laboratory certificate supplied by the seller, or a professional-looking label are not substitutes for a Canadian authorization. The regulator cautions that product identity, concentration, sterility, storage and contamination may be uncertain. Injectable products create particular concern because sterility and accurate dose are essential.

Health Canada describes products promoted through websites and social media, sometimes with claims that they are “research” products or intended for laboratory use. Consumers may encounter them through fitness, cosmetic or weight-management channels. The notice does not provide a complete inventory of every product circulating in Canada, so pharmacists should avoid treating a short list—or the absence of a product from a list—as proof of safety.

Compounding is not a shortcut around review

Health Canada’s notice distinguishes authorized medicines from compounded preparations. Compounding can have a legitimate role when a prescriber identifies an individual patient need and a pharmacist prepares a suitable formulation within applicable professional and regulatory standards. It is not a route for turning an unreviewed commercial product into an approved drug, or for supplying mass-produced versions that bypass the authorization and manufacturing requirements. The regulator’s guidance should be read alongside provincial or territorial pharmacy standards and the specific facts of a prescription.

For patients, the practical question is not simply whether a product contains a peptide. It is what exact product they obtained, from whom, for what purpose, and whether a Canadian-authorized product or a properly prescribed preparation is involved. People who have used an online injectable and feel unwell should be directed to timely clinical care; urgent symptoms warrant emergency assessment. Pharmacists should not advise patients to stop an authorized prescribed treatment solely because it belongs to the same broad drug class as an unauthorized product.

Practice guidance for pharmacists

• When a patient asks about an online peptide, ask to see the package, label, invoice or website listing; record the exact name, claimed concentration, route, source and intended use rather than relying on a brand-like name alone.
• Check the product in Health Canada’s Drug Product Database or Licensed Natural Health Products Database, as applicable. Confirm that the authorization and dosage form match the item presented; a seller’s laboratory certificate is not proof of Canadian authorization.
• Explain that unauthorized status means Health Canada has not assessed that product through the applicable pathway. Discuss uncertainty around identity, strength, sterility, contamination and storage without implying that every peptide medicine or every compounded preparation is unauthorized.
• If compounding is being considered, confirm there is an individual patient-specific need and a valid prescription, then follow provincial or territorial compounding standards and your pharmacy’s quality procedures. Do not use compounding to supply a routine, mass-market substitute for an unauthorized commercial product.
• For suspected adverse reactions, product quality concerns or suspected unauthorized products, document the details and report through the appropriate Health Canada reporting channel; arrange clinical assessment when needed and escalate urgent symptoms immediately.

Health Canada says it is strengthening compliance and enforcement work and coordinating with provincial and territorial regulators. The notice does not identify a single clinical protocol for every product; pharmacists should consult the linked regulator guidance and current provincial standards when a specific product or prescription is involved.